Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 19/20 | 0.59 |
| ▸ | HTR2C | P28335 | 19/20 | 0.59 |
| ▸ | HTR2B | P41595 | 19/20 | 0.59 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1173167 | 1.00 | HTR2A (0.59) | HTR2AHTR2CHTR2BCHRNB4CHRNA3 | |
| SCHEMBL1173166 | 1.00 | HTR2A (0.59) | HTR2AHTR2CHTR2BCHRNB4CHRNA3 | |
| SCHEMBL1173164 | 1.00 | HTR2A (0.59) | HTR2AHTR2CHTR2BCHRNB4CHRNA3 | |
| SCHEMBL1226267 | 0.83 | HTR2C (0.42) | HTR2AHTR2CHTR2BCHRNB4CHRNA3 | |
| SCHEMBL1226161 | 0.83 | HTR2C (0.42) | HTR2AHTR2CHTR2BCHRNB4CHRNA3 | |
| SCHEMBL244301 | 0.83 | HTR2C (0.42) | HTR2AHTR2CHTR2BCHRNB4CHRNA3 | |
| SCHEMBL1226270 | 0.83 | HTR2C (0.42) | HTR2AHTR2CHTR2BCHRNB4CHRNA3 | |
| SCHEMBL292288 | 0.83 | HTR2C (0.42) | HTR2AHTR2CHTR2BCHRNB4CHRNA3 | |
| SCHEMBL1226165 | 0.83 | HTR2C (0.42) | HTR2AHTR2CHTR2BCHRNB4CHRNA3 | |
| SCHEMBL31647704 | 0.81 | HTR2C (0.47) | HTR2AHTR2CHTR2BCHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275753-A1 | ORTHO-SUBSTITUTED ANILINE DERIVATIVE AND ANTIOXIDANT DRUG | NIPPON SODA CO., LTD. (JP) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275753-A1 | ORTHO-SUBSTITUTED ANILINE DERIVATIVE AND ANTIOXIDANT DRUG | NFE2L2, OXSR1, AOX1 | HTR2A 3593/4885HTR2C 3999/4885HTR2B 3006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.